Skip to content Skip to footer

2013

Journal Article

The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors

Byron, Sara A., Chen, Huaibin, Wortmann, Andreas, Loch, David, Gartside, Michael G., Dehkhoda, Farhad, Blais, Steven P., Neubert, Thomas A., Mohammadi, Moosa and Pollock, Pamela M. (2013). The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. NeoPlasia, 15 (8), 975-988. doi: 10.1593/neo.121106

The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors